Arcutis Biotherapeutics (ARQT) Net Cash Flow (2019 - 2026)

Arcutis Biotherapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$8.0 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 55.99% year-over-year to -$8.0 million; the TTM figure through Mar 2026 stood at -$18.7 million (up 86.34% YoY), while the FY2025 annual figure was -$28.9 million, down 68.68% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$8.0 million, down from -$4.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $101.5 million in Q1 2024, with the low at -$105.8 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$8.0 million (2026), against an average of -$3.7 million.
• Peak annual rise in Net Cash Flow reached 1975.78% in 2024, while the deepest fall reached 546.42% in 2024.
• Arcutis Biotherapeutics' Net Cash Flow stood at -$27.9 million in 2022, then jumped by 31.4% to -$19.1 million in 2023, then plunged by 230.61% to -$63.3 million in 2024, then surged by 93.25% to -$4.3 million in 2025, then plunged by 87.87% to -$8.0 million in 2026.
• Business Quant data shows ARQT's Net Cash Flow at -$8.0 million in Q1 2026, -$4.3 million in Q4 2025, and -$25.5 million in Q3 2025.